<code id='B66C36FDF7'></code><style id='B66C36FDF7'></style>
    • <acronym id='B66C36FDF7'></acronym>
      <center id='B66C36FDF7'><center id='B66C36FDF7'><tfoot id='B66C36FDF7'></tfoot></center><abbr id='B66C36FDF7'><dir id='B66C36FDF7'><tfoot id='B66C36FDF7'></tfoot><noframes id='B66C36FDF7'>

    • <optgroup id='B66C36FDF7'><strike id='B66C36FDF7'><sup id='B66C36FDF7'></sup></strike><code id='B66C36FDF7'></code></optgroup>
        1. <b id='B66C36FDF7'><label id='B66C36FDF7'><select id='B66C36FDF7'><dt id='B66C36FDF7'><span id='B66C36FDF7'></span></dt></select></label></b><u id='B66C36FDF7'></u>
          <i id='B66C36FDF7'><strike id='B66C36FDF7'><tt id='B66C36FDF7'><pre id='B66C36FDF7'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:knowledge    Page View:452
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In